Bing

SEARCH HISTORY

Exelixis (NASDAQ:EXEL) is one of today's best performing low-priced stocks, up 9.5% to $3.45 on 1.1x average daily volume. Exelixis has traded 3.8 million shares thus far today, vs. average volume of 3.6 million shares per day. The stock has outperformed ...
Financial News Network Online · ByRobert Cotter · 1/6/2015
AngioDynamics (ANGO) has entered into a worldwide licensing agreement with privately-held EmboMedics Inc. AngioDynamics will make an initial $2 million equity investment in EmboMedics through the purchase of preferred stock ... Inc.'s (EXEL) drug …
Realtime Business News · 4/10/2015
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on EXEL at http://www.zacks.com/ap/EXEL Keywords: Exelixis, Earnings Report
Yahoo Singapore Finance · 4/30/2015
More from Bing News
It's time for the Lightning Round. Cramer makes the call on viewer favorites. General Electric (GE): It's been a terrible stock lately ... I'd take a look. Exelixis (EXEL): I think it's a decent spec, said Cramer. Year to date it's down, but I wouldn ...
CNBC · ByLee Brodie · 7/28/2014
Exelixis opened at $2.50 and the stock price declined $0.00 (%) to $2.69 during the market session. EXEL is trading between the range of $2.50 - $2.75. Performance indicators show that the stock has gained 65.03% within the last month. Volume is 5.
AVAFIN · 2/25/2015
The stock is trading 5.2% above its 200-day moving average. Exelixis (EXEL) is trading down on a volume of 4.1 million, or 1.9 times its normal daily volume. The stock is down 8.6% to $5.10. Shares are down $1.35 (-20.9%) from a price of $6.45 on July 30 ...
Fox Business · 8/6/2012
Liquor retailers across New Hampshire were warned to stock up before switching to a new statewide warehouse ... The transition from Law Warehouse in Nashua to a new operation run by shipping giant Exel out of a massive warehouse in Bow has led to a …
Nashua Telegraph · 11/17/2013
Exelixis, Inc. (NASDAQ: EXEL) 11.1% HIGHER; announced positive results from a phase 2 clinical study evaluating cabozantinib as a treatment for EGFR wild-type non-small cell lung cancer (NSCLC). The trial, Study E1512, is a randomized phase 2 trial …
StreetInsider · 6/1/2015
That's unfortunate because investors are throwing a ton of money at prostate cancer stocks. Understanding what happens in ... Dendreon is learning this the hard way. Exelixis (EXEL) is having valuation problems because of this. Cell Genesys and Novacea ...
Minyanville · 5/21/2012
Japan Post, an enormous state-owned conglomerate that includes banks and even hospitals as part of its portfolio, is looking to hive off its post and logistics operations in a stock market ... Global Logistics and Toll Global Forwarding “The wheels ...
theloadstar.co.uk · 2/18/2015